Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-07-17

Clinical Trial Update: Effect of Evolocumab on Coronary Atherosclerosis [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating evolocumab for its effect on coronary atherosclerosis has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Repatha (Evolocumab)

Snippet

Sponsor: Cedars-Sinai Medical Center | Conditions: Cardiovascular Disease, Hyperlipidemia | Phase 3 | Status: COMPLETED | Results posted: 2024-07-17